Free Trial
LON:SUMM

Summit Therapeutics (SUMM) Share Price, News & Analysis

Summit Therapeutics logo

About Summit Therapeutics Stock (LON:SUMM)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
20.50
20.50
52-Week Range
N/A
Volume
280,318 shs
Average Volume
382,504 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Receive SUMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SUMM Stock News Headlines

Summit Therapeutics shares tumble following interim analysis
Summit Therapeutics sinks after STAT report on ivonescimab data
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Elon Musk has done it again. He’s developed a powerful new AI model that’s already turning heads — and turning the industry upside down. Some say it could threaten Google’s search engine dominance. Others believe it could mark the beginning of the end for ChatGPT.
Summit Therapeutics says new ivonescimab data clinically meaningful
Summit Therapeutics: New Ivonescimab Data Raise Concerns
Evercore ISI Remains a Buy on Summit Therapeutics (SMMT)
See More Headlines

SUMM Stock Analysis - Frequently Asked Questions

Summit Therapeutics PLC (LON:SUMM) issued its earnings results on Wednesday, June, 12th. The company reported ($3.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.00) by $1.00.

Shares of SUMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Summit Therapeutics (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Academy Sports and Outdoors (ASO), Diana Shipping (DSX), 2570 (JLF.L) (JLF) and National Fuel Gas (NFG).

Company Calendar

Last Earnings
6/12/2019
Today
4/26/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drugs - Generic
Sub-Industry
N/A
Current Symbol
LON:SUMM
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (LON:SUMM) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners